Sofosbuvir –velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals

ConclusionSofosbuvir –velpatasvir plus ribavirin was highly effective and well tolerated in Japanese patients who previously failed a DAA-based regimen. Baseline NS5A RASs did not affect treatment outcomes.

Source: Hepatology International - July 20, 2018 Category: Infectious Diseases Source Type: research